Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Patrick Y. Wen, MD


Neuro-oncology

Make an Appointment
Watch Video

Physician

  • Director, Center for Neuro-Oncology
  • Institute Physician
  • Professor of Neurology, Harvard Medical School

Centers/Programs

Clinical Interests

  • Brain and leptomeningeal metastases
  • Neurologic complications in cancer patients
  • Paraneoplastic syndromes
  • Primary brain and spinal cord tumors including gliomas, glioblastoma, primary CNS lymphoma, and ependymoma

Diseases Treated

  • Brain Metastasis
  • Brain Tumors
  • Glioblastoma
  • Low-Grade Glioma
  • Lymphoma, Primary CNS
  • Meningioma

Contact Information

  • Appointments617-632-2166
  • Office Phone Number617-632-2166
  • Fax617-632-4773

Bio

Dr. Wen graduated from the Medical College of St. Bartholomew's Hospital, University of London, in 1981. He completed his internal medicine training at the University of London postgraduate hospitals and his neurology residency in the Harvard-Longwood Neurology Training Program. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer.

Board Certification:

  • Neurology, 1989
  • Neuro-Oncology

Fellowship:

  • Harvard Medical School, Neurology

Residency:

  • Harvard-Longwood Neurology Training Program, Neurology
  • University of London, Internal Medicine

Medical School:

  • University of London

Research

Novel Therapies For Adult Brain Tumors

The primary goal of our multidisciplinary group of investigators is to find more effective treatments for patients with brain tumors. Our program is especially interested in the development of novel targeted molecular therapies. We currently have a large number of clinical trials of these agents in progress. Recently we also started trials of combinations of targeted molecular agents, which are likely to be more effective than treatment with single agents alone. As part of these trials, we are also genotyping the tumors and correlating them with response to treatment in the hope of identifying subgroups of patients who are particularly likely to benefit. In addition, we are conducting clinical trials evaluating novel inhibitors of angiogenesis, chemotherapy combinations, intratumoral agents delivered by convection, and tumor vaccines. A second focus of our program is the development of novel therapies for meningiomas, brain metastases, and leptomeningeal metastases; clinical studies evaluating targeted molecular agents and novel chemotherapeutic agents against these cancers are under way. We also collaborate with colleagues in Pediatric Neuro-Oncology and the Department of Cancer Biology in a preclinical program directed at identifying novel targets for therapy and evaluating new agents for clinical trials.In addition, our program has a strong interest in quality-of-life issues affecting patients with brain tumors, in particular, venous thromboembolic disease. We are currently studying the molecular basis of venous thromboembolism and evaluating the benefit of prophylactic anticoagulation. Furthermore, we are about to begin studies evaluating the role of prophylactic anticonvulsants in patients with malignant glioma who have not had seizures and medications such as methylphenidate for radiation-induced fatigue.

Tumors of the Spinal Cord. Neurology: Basic and Clinical Neurosciences. 2050.

Neurological Complications of Oncological therapy. Turner CD, Goldman S, editors. Late Effects of Treatment for Brain Tumors. 2050.

Inhibiting Angiogenesis in Malignant Gliomas. Griswold W, Soffieti R, editors. handbook of Clinical Neurology: Neuro-Oncology. 2050.

CNS toxicities from cancer therapy. Neurologic Clinics. 2050.

Brain Tumors in Adults. Neurologic Clinics. 2050.

Neurologic complications of Bone Marrow Transplantation. Schiff D, Kesari S, Wen PY, editors. Cancer Neurology in Clinical Practice. 2050.

Targeted Molecular Therapies for Meningiomas. Nurosurg Focus. 2050.

Therapy for Peritumoral Edema in High Grade Gliomas. Rivista Medica. 2050.

Cancer Neurology. Samuels MA, editor. Neurology for the Practicing Physician. 2050.

Antiangiogenic Therapy for malignant Gliomas. Expert Rev in AntiCancer Therapy. 2050.

Neurologic Complications of Chemotherapy. Schiff D, Kesari S, Wen PY, editors. Cancer Neurology in Clinical Practice. 2050.

Neurological Complications of Oncology Therapy. Newton h, Jolesz F, editors. Handbook fo neuro-Oncology Neuro-Imaging. 2050.

Nervous System Metastases. Bradley W, daroff R, Fenichel G, Jankovic J, editors. Neurology in Clinical Practice. 2050.

Neurologic complications of chemotherpay. Newton H, Malkin M, editors. Neurologic complications of systemic cancer and antineoplastic therapy. 2050.

Neurologic Complications of Prostate Cancer. Kantoff PW, Carroll P, D'Amico A, editors. Prostate Cancer. 2050.

Cancer Neurology in Clinical Practice. 2050.

Novel Therapies in Brain Tumors. Neurol Clin. 2050.

Telomerase as a therapeutic target in glioblastoma. Neuro Oncol. 2021 Sep 02.
View in: PubMed

Multimodal platform for assessing drug distribution and response in clinical trials. Neuro Oncol. 2021 Aug 12.
View in: PubMed

The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications. Neuro Oncol. 2021 08 02; 23(8):1215-1217.
View in: PubMed

Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. Neuro Oncol. 2021 08 02; 23(8):1252-1260.
View in: PubMed

Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer. 2021 Jul; 9(7).
View in: PubMed

SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 2021 Jun 26.
View in: PubMed

Deep Learning-Based Automatic Tumor Burden Assessment of Pediatric High-Grade Gliomas, Medulloblastomas, and Other Leptomeningeal Seeding Tumors. Neuro Oncol. 2021 Jun 26.
View in: PubMed

Analysis of morphological characteristics of IDH-mutant/wildtype brain tumors using whole-lesion phenotype analysis. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab088.
View in: PubMed

Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab082.
View in: PubMed

The Use of External Control Data for Predictions and Futility Interim Analyses in Clinical Trials. Neuro Oncol. 2021 Jun 09.
View in: PubMed

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clin Cancer Res. 2021 Aug 15; 27(16):4491-4499.
View in: PubMed

Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results. Neuro Oncol. 2021 May 20.
View in: PubMed

Epidemiology of Brain Metastases and Leptomeningeal Disease. Neuro Oncol. 2021 Apr 28.
View in: PubMed

Positron emission tomography imaging of drug concentrations in the brain. Neuro Oncol. 2021 04 12; 23(4):537-538.
View in: PubMed

Population-based estimates of survival among elderly patients with brain metastases. Neuro Oncol. 2021 04 12; 23(4):661-676.
View in: PubMed

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET. Sci Rep. 2021 Apr 07; 11(1):7632.
View in: PubMed

IDH-mutant gliomas with additional class-defining molecular events. Mod Pathol. 2021 Jul; 34(7):1236-1244.
View in: PubMed

Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. Neuro Oncol. 2021 03 25; 23(3):506-507.
View in: PubMed

Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375.
View in: PubMed

A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro Oncol. 2021 03 25; 23(3):468-477.
View in: PubMed

Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. J Neurooncol. 2021 May; 152(3):515-522.
View in: PubMed

Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. Neuro Oncol. 2021 02 25; 23(2):189-198.
View in: PubMed

Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. Neurooncol Pract. 2021 Aug; 8(4):417-425.
View in: PubMed

Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab029.
View in: PubMed

Osteogenic effects of the peptide fraction derived from pepsin-hydrolyzed bovine lactoferrin. J Dairy Sci. 2021 Apr; 104(4):3853-3862.
View in: PubMed

Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma. Sci Rep. 2021 01 27; 11(1):2306.
View in: PubMed

Seizures Among Patients with Brain Metastases: A Population- and Institutional-level Analysis. Neurology. 2021 Jan 05.
View in: PubMed

Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro Oncol. 2020 12 18; 22(12):1822-1830.
View in: PubMed

Response to Letter to Editor. Neuro Oncol. 2020 11 26; 22(11):1706-1707.
View in: PubMed

Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neuro Oncol. 2020 11 26; 22(11):1568-1579.
View in: PubMed

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2021 02 15; 27(4):1048-1057.
View in: PubMed

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 11 02; 18(11):1537-1570.
View in: PubMed

Adult precision medicine: learning from the past to enhance the future. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdaa145.
View in: PubMed

Utility of claims data for delineation of intracranial treatment among patients with brain metastases. Neuro Oncol. 2020 10 14; 22(10):1547-1548.
View in: PubMed

Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery. Neuro Oncol. 2020 10 14; 22(10):1422-1424.
View in: PubMed

Evaluation of RAPNO criteria in medulloblastoma and other leptomeningeal seeding tumors using MRI and clinical data. Neuro Oncol. 2020 10 14; 22(10):1536-1544.
View in: PubMed

Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. Cell Rep. 2020 09 29; 32(13):108196.
View in: PubMed

Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro Oncol. 2020 09 29; 22(9):1262-1275.
View in: PubMed

Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa124.
View in: PubMed

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020 09; 21(9):1234-1243.
View in: PubMed

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020 08 17; 22(8):1073-1113.
View in: PubMed

Metallic Glacial Glass Formation by a First-Order Liquid-Liquid Transition. J Phys Chem Lett. 2020 Aug 20; 11(16):6718-6723.
View in: PubMed

Gender and sex disparity in cancer trials. ESMO Open. 2020 08; 5(Suppl 4):e000773.
View in: PubMed

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. ESMO Open. 2020 07; 5(4).
View in: PubMed

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. ESMO Open. 2020 07; 5(4).
View in: PubMed

Neurologic Complications of Cranial Radiation Therapy and Strategies to Prevent or Reduce Radiation Toxicity. Curr Neurol Neurosci Rep. 2020 06 29; 20(8):34.
View in: PubMed

Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. J Clin Oncol. 2020 10 10; 38(29):3398-3406.
View in: PubMed

Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro Oncol. 2020 06 09; 22(6):757-772.
View in: PubMed

Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
View in: PubMed

Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020 06; 21(6):e317-e329.
View in: PubMed

Optimization of ultraviolet Raman spectroscopy for trace explosive checkpoint screening. Anal Bioanal Chem. 2020 Jul; 412(19):4495-4504.
View in: PubMed

Novel Therapies for Glioblastoma. Curr Neurol Neurosci Rep. 2020 05 22; 20(7):19.
View in: PubMed

Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro Oncol. 2020 05 15; 22(5):601-612.
View in: PubMed

Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. Neuro Oncol. 2020 05 15; 22(5):694-704.
View in: PubMed

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro Oncol. 2020 05 15; 22(5):705-717.
View in: PubMed

Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):716-724.
View in: PubMed

Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas. Neuro Oncol. 2020 May 05.
View in: PubMed

A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly. Neuro Oncol. 2020 Apr 27.
View in: PubMed

Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
View in: PubMed

Toward a standard pathological and molecular characterization of recurrent glioma in adults: a Response Assessment in Neuro-Oncology effort. Neuro Oncol. 2020 04 15; 22(4):450-456.
View in: PubMed

Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. Clin Cancer Res. 2020 07 01; 26(13):3135-3144.
View in: PubMed

NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.
View in: PubMed

Fertility preservation outcomes in women with gliomas: a retrospective case-control study. J Neurooncol. 2020 Apr; 147(2):371-376.
View in: PubMed

Meta-analysis of prophylactic cranial irradiation or not in treatment of extensive-stage small-cell lung cancer: The dilemma remains. Cancer Radiother. 2020 Feb; 24(1):44-52.
View in: PubMed

Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. Lancet Oncol. 2020 02; 21(2):e97-e103.
View in: PubMed

Highlights of the 2019 Society for Neuro-Oncology Inaugural Brain Metastases Conference: establishing a dedicated meeting to address an unmet need in the field. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa036.
View in: PubMed

First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. Clin Cancer Res. 2020 04 15; 26(8):1820-1828.
View in: PubMed

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol. 2020 01 11; 22(1):94-102.
View in: PubMed

Medical management of meningiomas. Handb Clin Neurol. 2020; 170:291-302.
View in: PubMed

Glioma progression through synaptic activity. Nat Rev Neurol. 2020 Jan; 16(1):6-7.
View in: PubMed

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro Oncol. 2019 12 17; 21(12):1498-1508.
View in: PubMed

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol. 2020 Jan; 146(1):79-89.
View in: PubMed

Imaging of Central Nervous System Tumors Based on the 2016 World Health Organization Classification. Neurol Clin. 2020 02; 38(1):95-113.
View in: PubMed

Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. Neuro Oncol. 2019 11 04; 21(11):1412-1422.
View in: PubMed

To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. Neuro Oncol. 2019 10 09; 21(10):1239-1249.
View in: PubMed

Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019 Nov; 80:101896.
View in: PubMed

Provider-reported challenges and barriers to referring patients to neuro-oncology clinical trials: a report from the Society for Neuro-Oncology member survey. Neurooncol Pract. 2020 Jan; 7(1):38-51.
View in: PubMed

Barriers to accrual and enrollment in brain tumor trials. Neuro Oncol. 2019 09 06; 21(9):1100-1117.
View in: PubMed

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 09 01; 85(3):E607-E608.
View in: PubMed

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol. 2019 Oct; 145(1):97-105.
View in: PubMed

Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med. 2019 10; 8(13):5988-5994.
View in: PubMed

Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. Cancer Res. 2019 10 01; 79(19):5088-5101.
View in: PubMed

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 2019 08 14; 11(505).
View in: PubMed

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clin Cancer Res. 2019 10 01; 25(19):5799-5807.
View in: PubMed

Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. Neuro Oncol. 2019 07 11; 21(7):837-853.
View in: PubMed

Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. Clin Cancer Res. 2019 08 15; 25(16):4993-5001.
View in: PubMed

Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. Cureus. 2019 May 23; 11(5):e4726.
View in: PubMed

The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. Neuro Oncol. 2019 05 06; 21(5):648-658.
View in: PubMed

A low percentage of metastases in deep brain and temporal lobe structures. Neuro Oncol. 2019 05 06; 21(5):640-647.
View in: PubMed

Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro Oncol. 2019 05 06; 21(5):571-584.
View in: PubMed

Thrombotic Complications in Gliomas. Semin Thromb Hemost. 2019 Jun; 45(4):326-333.
View in: PubMed

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Invest New Drugs. 2020 04; 38(2):433-444.
View in: PubMed

[The status quo of amphetamine type stimulants use among residents aged 15-64 in a border city of Yunnan province, 2014]. Zhonghua Liu Xing Bing Xue Za Zhi. 2019 Apr 10; 40(4):446-450.
View in: PubMed

Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3.
View in: PubMed

Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. 2019 03 01; 8(1):CNS28.
View in: PubMed

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol. 2019 02 14; 21(2):167-178.
View in: PubMed

Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. Neuro Oncol. 2019 02 14; 21(2):234-241.
View in: PubMed

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486.
View in: PubMed

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
View in: PubMed

Local control after brain-directed radiation in patients with cystic versus solid brain metastases. J Neurooncol. 2019 Apr; 142(2):355-363.
View in: PubMed

Molecular and translational advances in meningiomas. Neuro Oncol. 2019 01 14; 21(Suppl 1):i4-i17.
View in: PubMed

Advances in multidisciplinary therapy for meningiomas. Neuro Oncol. 2019 01 14; 21(Suppl 1):i18-i31.
View in: PubMed

Imaging and diagnostic advances for intracranial meningiomas. Neuro Oncol. 2019 01 14; 21(Suppl 1):i44-i61.
View in: PubMed

Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. Nat Biomed Eng. 2019 03; 3(3):230-245.
View in: PubMed

The lomustine crisis: awareness and impact of the 1500% price hike. Neuro Oncol. 2019 01 01; 21(1):1-3.
View in: PubMed

The lomustine crisis: awareness and impact of the 1500% price hike. Neuro Oncol. 2019 Jan 01; 21(1):1-3.
View in: PubMed

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2019 01 01; 21(1):26-36.
View in: PubMed

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
View in: PubMed

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clin Cancer Res. 2019 04 01; 25(7):2305-2313.
View in: PubMed

Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. J Neurooncol. 2019 Mar; 142(1):69-77.
View in: PubMed

Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis Oncol. 2018; 2018.
View in: PubMed

Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. AJR Am J Roentgenol. 2018 12; 211(6):1342-1347.
View in: PubMed

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol. 2018 09 03; 20(10):1411-1418.
View in: PubMed

PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology. 2018 10 02; 91(14):e1355-e1359.
View in: PubMed

The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro Oncol. 2018 08 02; 20(9):1162-1172.
View in: PubMed

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250.
View in: PubMed

Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. Neuro Oncol. 2018 08 02; 20(9):1262-1271.
View in: PubMed

Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology. 2018 08 28; 91(9):403-413.
View in: PubMed

Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas? Neuro Oncol. 2018 07 05; 20(8):1144.
View in: PubMed

The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018 07 05; 20(8):1034-1043.
View in: PubMed

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res. 2018 10 01; 24(19):4643-4649.
View in: PubMed

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2018 06 18; 20(7):897-906.
View in: PubMed

The Interface Between Neurology and Oncology. Neurol Clin. 2018 08; 36(3):xiii-xiv.
View in: PubMed

Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition. Clin Exp Dermatol. 2018 Dec; 43(8):890-894.
View in: PubMed

Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma? Curr Treat Options Neurol. 2018 Apr 18; 20(5):14.
View in: PubMed

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018 04 16; 9(1):1474.
View in: PubMed

Ultrastable metallic glasses formed on cold substrates. Nat Commun. 2018 04 11; 9(1):1389.
View in: PubMed

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro Oncol. 2018 04 09; 20(5):666-673.
View in: PubMed

Toward methylation-based classification of central nervous system tumors. Neuro Oncol. 2018 04 09; 20(5):579-581.
View in: PubMed

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol. 2018 03 27; 20(4):546-556.
View in: PubMed

Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro Oncol. 2018 03 27; 20(4):457-471.
View in: PubMed

[Effects of sural nerve nutrition vess els-supported flap for reconstruction of distal lower leg and ankle soft tissue defects]. Zhonghua Yi Xue Za Zhi. 2018 Mar 20; 98(11):842-845.
View in: PubMed

Imaging Criteria in Neuro-oncology. Semin Neurol. 2018 02; 38(1):24-31.
View in: PubMed

Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. Lancet Oncol. 2018 03; 19(3):e173-e180.
View in: PubMed

Imaging in neuro-oncology. Ther Adv Neurol Disord. 2018; 11:1756286418759865.
View in: PubMed

Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiother Oncol. 2018 03; 126(3):511-518.
View in: PubMed

Antiangiogenic Therapy of High-Grade Gliomas. Prog Neurol Surg. 2018; 31:180-199.
View in: PubMed

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):259-267.
View in: PubMed

Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol. 2018 01 22; 20(2):225-235.
View in: PubMed

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):249-258.
View in: PubMed

The siren song of bevacizumab: swan song or clarion call? Neuro Oncol. 2018 01 22; 20(2):147-148.
View in: PubMed

Meeting Update-Society for Neuro-Oncology 2017 Annual Meeting. Neuro Oncol. 2018 01 22; 20(2):156-159.
View in: PubMed

Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro Oncol. 2018 01 10; 20(1):13-23.
View in: PubMed

Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018 01; 19(1):e33-e42.
View in: PubMed

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018 01; 19(1):e20-e32.
View in: PubMed

Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. 2018 04 01; 124(7):1438-1448.
View in: PubMed

2016 World Health Organization Classification of Central Nervous System Tumors. Continuum (Minneap Minn). 2017 12; 23(6, Neuro-oncology):1531-1547.
View in: PubMed

Transition: Message from the Editor-in-Chief. Neuro Oncol. 2017 11 29; 19(12):1567.
View in: PubMed

Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2017 Nov 29; 19(12):1688-1697.
View in: PubMed

Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging. Clin Cancer Res. 2018 03 01; 24(5):1073-1081.
View in: PubMed

Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS One. 2017; 12(11):e0187908.
View in: PubMed

NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 11; 15(11):1331-1345.
View in: PubMed

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018 01 01; 36(1):7-13.
View in: PubMed

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018 01 15; 24(2):295-305.
View in: PubMed

Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017 Oct 19; 19(11):1511-1521.
View in: PubMed

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. J Neurooncol. 2018 Jan; 136(1):79-86.
View in: PubMed

Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. J Neurooncol. 2017 Dec; 135(3):581-591.
View in: PubMed

Adjuvant treatments for ependymomas. J Neurosurg Sci. 2018 Feb; 62(1):71-77.
View in: PubMed

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res. 2018 02 15; 24(4):737-743.
View in: PubMed

Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. JAMA Oncol. 2017 Aug 01; 3(8):1069-1077.
View in: PubMed

Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):908-917.
View in: PubMed

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 01; 23(19):5745-5756.
View in: PubMed

Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol. 2017 Jul 20; 35(21):2439-2449.
View in: PubMed

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. 2017; 1.
View in: PubMed

Immunomodulation for glioblastoma. Curr Opin Neurol. 2017 06; 30(3):361-369.
View in: PubMed

Relaxation Decoupling in Metallic Glasses at Low Temperatures. Phys Rev Lett. 2017 Jun 02; 118(22):225901.
View in: PubMed

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 Oct 03; 8(45):79298-79304.
View in: PubMed

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 May 12.
View in: PubMed

Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert Rev Anticancer Ther. 2017 Jun; 17(6):507-515.
View in: PubMed

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2017 05 01; 19(5):625-635.
View in: PubMed

A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro Oncol. 2017 05 01; 19(5):614-624.
View in: PubMed

How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies. Neuro Oncol. 2017 04 01; 19(4):459-460.
View in: PubMed

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-ß tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro Oncol. 2017 04 01; 19(4):567-575.
View in: PubMed

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
View in: PubMed

Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics. 2017 04; 14(2):307-320.
View in: PubMed

Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol. 2017 04 01; 19(4):484-492.
View in: PubMed

The Viral Connection to Glioblastoma. Curr Infect Dis Rep. 2017 Feb; 19(2):5.
View in: PubMed

Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 03; 132(1):181-188.
View in: PubMed

Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol. 2017 Mar; 111:60-65.
View in: PubMed

Bose-Einstein Condensation of Long-Lifetime Polaritons in Thermal Equilibrium. Phys Rev Lett. 2017 Jan 06; 118(1):016602.
View in: PubMed

Clinical Relevance of Steroid Use in Neuro-Oncology. Curr Neurol Neurosci Rep. 2017 01; 17(1):5.
View in: PubMed

Message from the Editor-in-Chief. Neuro Oncol. 2017 01; 19(1):1.
View in: PubMed

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. J Neurooncol. 2017 02; 131(3):603-610.
View in: PubMed

Emerging targeted therapies for glioma. Expert Opin Emerg Drugs. 2016 Dec; 21(4):441-452.
View in: PubMed

Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2016 11; 29(6):627-642.
View in: PubMed

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol. 2016 Nov; 34(11):1161-1167.
View in: PubMed

Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro Oncol. 2017 01; 19(1):12-21.
View in: PubMed

Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints. Magn Reson Imaging Clin N Am. 2016 Nov; 24(4):705-718.
View in: PubMed

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro Oncol. 2017 01; 19(1):89-98.
View in: PubMed

Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016 12; 130(3):495-503.
View in: PubMed

Corticosteroids for peritumoral edema: time to overcome our addiction? Neuro Oncol. 2016 09; 18(9):1191-2.
View in: PubMed

Updates in the management of brain metastases. Neuro Oncol. 2016 08; 18(8):1043-65.
View in: PubMed

A 3-dimensional DTI MRI-based model of GBM growth and response to radiation therapy. Int J Oncol. 2016 Sep; 49(3):1081-7.
View in: PubMed

Assessment of Brain Tumor Response: RANO and Its Offspring. Curr Treat Options Oncol. 2016 07; 17(7):35.
View in: PubMed

Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017 01; 19(1):109-117.
View in: PubMed

MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget. 2016 Jun 14; 7(24):37054-37063.
View in: PubMed

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discov. 2016 07; 6(7):740-53.
View in: PubMed

Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol. 2016 12; 18(12):1680-1687.
View in: PubMed

Memory Effect Manifested by a Boson Peak in Metallic Glass. Phys Rev Lett. 2016 Apr 29; 116(17):175901.
View in: PubMed

Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):217-225.
View in: PubMed

Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis. Eur Rev Med Pharmacol Sci. 2016 Mar; 20(5):866-72.
View in: PubMed

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). Neuro Oncol. 2016 Mar; 18 Suppl 2:ii26-ii36.
View in: PubMed

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro Oncol. 2016 06; 18(6):849-54.
View in: PubMed

Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res. 2016 06 15; 22(12):2885-96.
View in: PubMed

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55.
View in: PubMed

Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagn Pathol. 2016 Jan 27; 11:13.
View in: PubMed

Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016 Feb; 12(2):69-70.
View in: PubMed

Message from the Editor-in-Chief. Neuro Oncol. 2016 Jan; 18(1):1.
View in: PubMed

Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. 2016 Feb 15; 122(4):582-7.
View in: PubMed

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
View in: PubMed

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-e542.
View in: PubMed

CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro Oncol. 2015 Nov; 17 Suppl 6:vi1-26.
View in: PubMed

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81.
View in: PubMed

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin Cancer Res. 2016 Mar 01; 22(5):1185-96.
View in: PubMed

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016 Apr; 18(4):557-64.
View in: PubMed

Central Nervous System Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Oct; 13(10):1191-202.
View in: PubMed

Response Assessment in Neuro-Oncology (RANO): more than imaging criteria for malignant glioma. Neurooncol Pract. 2015 Dec; 2(4):205-209.
View in: PubMed

Author response. Neurology. 2015 Sep 22; 85(12):1090.
View in: PubMed

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Sep 22; 85(12):1090.
View in: PubMed

A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
View in: PubMed

Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015 Dec 15; 121(24):4376-81.
View in: PubMed

Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer. Cancer. 2015 Dec 01; 121(23):4165-72.
View in: PubMed

Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. J Clin Oncol. 2015 Oct 01; 33(28):3186-92.
View in: PubMed

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015 Sep; 17(9):1188-98.
View in: PubMed

Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7.
View in: PubMed

Glioma. Nat Rev Dis Primers. 2015 07 16; 1:15017.
View in: PubMed

Controversies in neuro-oncology: role of whole-brain radiation therapy in the treatment of newly diagnosed brain metastases. Neuro Oncol. 2015 Jul; 17(7):915.
View in: PubMed

Radiotherapy and death from cerebrovascular disease in patients with primary brain tumors. J Neurooncol. 2015 Sep; 124(2):291-7.
View in: PubMed

Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J Neurooncol. 2015 Aug; 124(1):137-46.
View in: PubMed

One size should not fit all: advancing toward personalized glioblastoma therapy. Discov Med. 2015 Jun; 19(107):471-7.
View in: PubMed

Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients. Transl Oncol. 2015 Jun; 8(3):137-46.
View in: PubMed

Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015 Jun; 16(6):e270-8.
View in: PubMed

Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro Oncol. 2015 Sep; 17(9):1275-83.
View in: PubMed

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1386-92.
View in: PubMed

Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug; 17(8):1051-63.
View in: PubMed

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15; 21(16):3610-8.
View in: PubMed

Peroxynitrite decomposition catalyst prevents matrix metalloproteinase-9 activation and neurovascular injury after hemoglobin injection into the caudate nucleus of rats. Neuroscience. 2015 Jun 25; 297:182-93.
View in: PubMed

Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide. Oncology (Williston Park). 2015 Apr; 29(4):265, 275.
View in: PubMed

Patient management problem. Continuum (Minneap Minn). 2015 Apr; 21(2 Neuro-oncology):535-40.
View in: PubMed

Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9.
View in: PubMed

Patient management problem-preferred responses. Continuum (Minneap Minn). 2015 Apr; 21(2 Neuro-oncology):541-56.
View in: PubMed

How treatment monitoring is influencing treatment decisions in glioblastomas. Curr Treat Options Neurol. 2015 Apr; 17(4):343.
View in: PubMed

Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96.
View in: PubMed

Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
View in: PubMed

Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol. 2015; 6:33.
View in: PubMed

Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. Neuro Oncol. 2015 Aug; 17(8):1106-13.
View in: PubMed

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7.
View in: PubMed

Tanshinone IIA attenuates the cerebral ischemic injury-induced increase in levels of GFAP and of caspases-3 and -8. Neuroscience. 2015 Mar 12; 288:105-11.
View in: PubMed

Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol. 2015 Feb; 12(2):69-70.
View in: PubMed

Message from the Editor-in-Chief. Neuro Oncol. 2015 Jan; 17(1):1.
View in: PubMed

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015 Jan; 122(1):4-23.
View in: PubMed

Novel chemotherapeutic approaches in adult high-grade gliomas. Cancer Treat Res. 2015; 163:117-42.
View in: PubMed

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6.
View in: PubMed

Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J Neurooncol. 2015 Feb; 121(3):627-34.
View in: PubMed

Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 2015 Feb; 121(3):557-63.
View in: PubMed

Facing the future of brain tumor clinical research. Clin Cancer Res. 2014 Nov 15; 20(22):5591-600.
View in: PubMed

Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Nov; 12(11):1517-23.
View in: PubMed

Medical management of brain tumors and the sequelae of treatment. Neuro Oncol. 2015 Apr; 17(4):488-504.
View in: PubMed

Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. Oncotarget. 2014 Oct 30; 5(20):9811-22.
View in: PubMed

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015 Jan; 121(2):297-302.
View in: PubMed

Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii7-13.
View in: PubMed

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014 Oct; 16 Suppl 7:vii36-47.
View in: PubMed

Pros and cons of current brain tumor imaging. Neuro Oncol. 2014 Oct; 16 Suppl 7:vii2-11.
View in: PubMed

Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92.
View in: PubMed

Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer. 2015 Apr 01; 121(7):997-1007.
View in: PubMed

Immunotherapy advances for glioblastoma. Neuro Oncol. 2014 Nov; 16(11):1441-58.
View in: PubMed

Compositional origin of unusual ß-relaxation properties in La-Ni-Al metallic glasses. J Chem Phys. 2014 Aug 28; 141(8):084506.
View in: PubMed

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8.
View in: PubMed

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan; 17(1):116-21.
View in: PubMed

Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy. J Clin Oncol. 2016 Apr 01; 34(10):e87-9.
View in: PubMed

Point/counterpoint: is there a role for radiotherapy in the treatment of primary CNS lymphoma? Neuro Oncol. 2014 Aug; 16(8):1032.
View in: PubMed

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol. 2014 Nov; 16(11):1541-6.
View in: PubMed

Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12.
View in: PubMed

Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47.
View in: PubMed

Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9.
View in: PubMed

Profile of interdialytic ambulatory blood pressure in a cohort of Chinese patients. J Hum Hypertens. 2014 Nov; 28(11):677-83.
View in: PubMed

Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53.
View in: PubMed

Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol. 2014 Sep; 16(9):1176-85.
View in: PubMed

Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol. 2014 Aug; 119(1):149-58.
View in: PubMed

Spin-echo echo-planar perfusion prior to chemoradiation is a strong independent predictor of progression-free and overall survival in newly diagnosed glioblastoma. J Neurooncol. 2014 Aug; 119(1):111-9.
View in: PubMed

The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014 Jul; 118(3):557-99.
View in: PubMed

The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014 Jul; 118(3):501-55.
View in: PubMed

Bevacizumab for glioblastoma: what can we learn from patterns of progression? Neurology. 2014 May 13; 82(19):1670-1.
View in: PubMed

Targeted therapies: Further delineating bevacizumab's response spectrum. Nat Rev Clin Oncol. 2014 May; 11(5):243-4.
View in: PubMed

Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study. Epilepsy Res. 2014 Jul; 108(5):843-52.
View in: PubMed

A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. Indian J Cancer. 2014 Mar; 51 Suppl 3:e95-8.
View in: PubMed

Controversies in neuro-oncology: does valganciclovir have a role in the treatment of high-grade gliomas? Neuro Oncol. 2014 Mar; 16(3):329.
View in: PubMed

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014 Jun; 16(6):829-40.
View in: PubMed

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr; 16(4):567-78.
View in: PubMed

New editorial team for neuro-oncology. Neuro Oncol. 2014 Jan; 16(1):1.
View in: PubMed

Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs. 2014 Feb; 23(2):199-210.
View in: PubMed

Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. Oncologist. 2014 Jan; 19(1):75-81.
View in: PubMed

Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro Oncol. 2014 Jan; 16(2):173-8.
View in: PubMed

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64.
View in: PubMed

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e396-406.
View in: PubMed

Central nervous system cancers. J Natl Compr Canc Netw. 2013 Sep 01; 11(9):1114-51.
View in: PubMed

Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e407-16.
View in: PubMed

Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol. 2013 Nov; 115(2):267-76.
View in: PubMed

Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med. 2013 Sep; 19(9):1178-83.
View in: PubMed

The role of MGMT testing in clinical practice: a report of the association for molecular pathology. J Mol Diagn. 2013 Sep; 15(5):539-55.
View in: PubMed

Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol. 2013 Aug; 15(8):972-8.
View in: PubMed

Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J Neurooncol. 2013 Oct; 115(1):71-7.
View in: PubMed

Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013 Oct 01; 119(19):3479-88.
View in: PubMed

A simple technique for a new working heterotopic heart transplantation model in rats. Transplant Proc. 2013 Jul-Aug; 45(6):2522-6.
View in: PubMed

Treatment options in newly diagnosed glioblastoma. Curr Treat Options Neurol. 2013 Jun; 15(3):281-8.
View in: PubMed

An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun; 12(6):597-615.
View in: PubMed

RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):880-4.
View in: PubMed

Selective enhancements in 2D Fourier transform optical spectroscopy with tailored pulse shapes. J Phys Chem A. 2013 Jul 25; 117(29):6380-7.
View in: PubMed

Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs. 2013 Jun; 18(2):137-53.
View in: PubMed

Enhancing radiation therapy for patients with glioblastoma. Expert Rev Anticancer Ther. 2013 May; 13(5):569-81.
View in: PubMed

Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatr Blood Cancer. 2013 Sep; 60(9):1397-401.
View in: PubMed

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-5.
View in: PubMed

Current and future directions for Phase II trials in high-grade glioma. Expert Rev Neurother. 2013 Apr; 13(4):369-87.
View in: PubMed

PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion. J Neurooncol. 2013 May; 113(1):143-7.
View in: PubMed

Reply to B. Freidlin et al. J Clin Oncol. 2013 Mar 01; 31(7):970-1.
View in: PubMed

Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. J Neurosurg. 2013 Jun; 118(6):1183-7.
View in: PubMed

Quantitative analysis of pancreatic polypeptide cell distribution in the human pancreas. PLoS One. 2013; 8(1):e55501.
View in: PubMed

A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res. 2013 Feb 15; 19(4):900-8.
View in: PubMed

Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res. 2013 Mar 15; 19(6):1567-76.
View in: PubMed

Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol. 2013 Jun; 8(2):117-25.
View in: PubMed

A phase II trial of oral gimatecan for recurrent glioblastoma. J Neurooncol. 2013 Feb; 111(3):347-53.
View in: PubMed

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol. 2012 Dec; 14(12):1511-8.
View in: PubMed

The association between RhEPO and FN expression in glomerular mesangial cells. Panminerva Med. 2012 Sep; 54(3):205-9.
View in: PubMed

Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res. 2012 Nov 01; 18(21):6032-9.
View in: PubMed

Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98.
View in: PubMed

Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013 Jan; 54(1):58-61.
View in: PubMed

DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012; 7(6):e38881.
View in: PubMed

Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol. 2012 Jun; 14(6):761-7.
View in: PubMed

Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012 Sep 10; 30(26):3258-63.
View in: PubMed

Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 Jul; 14(7):819-29.
View in: PubMed

Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012 May; 13(5):e196-204.
View in: PubMed

Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012 Jul 01; 30(19):2307-13.
View in: PubMed

Central nervous system complications of cancer therapy. J Support Oncol. 2012 Jul-Aug; 10(4):133-41.
View in: PubMed

A novel treatment for glioblastoma: integrin inhibition. Expert Rev Neurother. 2012 Apr; 12(4):421-35.
View in: PubMed

Neurologic complications of cancer drug therapies. Continuum (Minneap Minn). 2012 Apr; 18(2):355-65.
View in: PubMed

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May; 2(5):458-71.
View in: PubMed

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012 07; 108(3):491-8.
View in: PubMed

Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol. 2012 Oct; 14(10):1203-14.
View in: PubMed

Epidemiology of brain metastases. Curr Oncol Rep. 2012 Feb; 14(1):48-54.
View in: PubMed

Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas. J Neurooncol. 2012 May; 107(3):565-70.
View in: PubMed

Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012 Jan; 70(1):234-43; discussion 243-4.
View in: PubMed

Inhibiting angiogenesis in malignant gliomas. Handb Clin Neurol. 2012; 104:279-308.
View in: PubMed

Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012 Apr; 26(4):595-608.
View in: PubMed

Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. . 2012 Jan; 158A(1):24-41.
View in: PubMed

Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012 Jan 15; 72(2):402-7.
View in: PubMed

Targeting DNA repair and the cell cycle in glioblastoma. J Neurooncol. 2012 May; 107(3):463-77.
View in: PubMed

Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012 Apr; 69(4):849-60.
View in: PubMed

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol. 2012 Mar; 107(1):133-8.
View in: PubMed

Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis. Oncologist. 2011; 16(10):1435-9.
View in: PubMed

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012 Jan; 106(2):409-15.
View in: PubMed

An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 2011 Oct; 1(5):442-56.
View in: PubMed

Valproic acid as the AED of choice for patients with glioblastoma? The jury is out. Neurology. 2011 Sep 20; 77(12):1114-5.
View in: PubMed

Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011 Oct; 13(10):1118-24.
View in: PubMed

It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3.
View in: PubMed

Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2012 Jan; 106(1):147-53.
View in: PubMed

Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol. 2012 Jan; 106(1):121-5.
View in: PubMed

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br J Cancer. 2011 Jun 28; 105(1):112-7.
View in: PubMed

Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res. 2011 Jul 15; 17(14):4872-81.
View in: PubMed

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011 Jun; 13(6):649-59.
View in: PubMed

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011 Jul 01; 29(19):2689-95.
View in: PubMed

Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas. J Clin Oncol. 2011 May 20; 29(15_suppl):2032.
View in: PubMed

Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM). J Clin Oncol. 2011 May 20; 29(15_suppl):2069.
View in: PubMed

Phase II study of dose-intense temozolomide in recurrent glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2038.
View in: PubMed

Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01. J Clin Oncol. 2011 May 20; 29(15_suppl):2039.
View in: PubMed

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2040.
View in: PubMed

Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2043.
View in: PubMed

A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). J Clin Oncol. 2011 May 20; 29(15_suppl):2050.
View in: PubMed

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jun; 13(6):660-8.
View in: PubMed

Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. Expert Rev Anticancer Ther. 2011 May; 11(5):653-6.
View in: PubMed

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011 Jun; 12(6):583-93.
View in: PubMed

Central nervous system cancers. J Natl Compr Canc Netw. 2011 Apr; 9(4):352-400.
View in: PubMed

Genetic alterations in pulmonary epithelioid hemangioendothelioma and epithelioid angiosarcoma. Histol Histopathol. 2011 04; 26(4):491-6.
View in: PubMed

Pronounced slow ß-relaxation in La-based bulk metallic glasses. J Phys Condens Matter. 2011 Apr 13; 23(14):142202.
View in: PubMed

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 May; 13(5):509-16.
View in: PubMed

Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia. 2011 Aug; 59(8):1205-12.
View in: PubMed

Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61.
View in: PubMed

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011 Apr; 13(4):437-46.
View in: PubMed

Response assessment in neuro-oncology. Curr Oncol Rep. 2011 Feb; 13(1):50-6.
View in: PubMed

Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol. 2011 Aug; 104(1):179-89.
View in: PubMed

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011 Jan 01; 71(1):19-28.
View in: PubMed

Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J Neurooncol. 2011 Aug; 104(1):287-91.
View in: PubMed

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010; 15(12):1329-34.
View in: PubMed

Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. J Neurooncol. 2011 Aug; 104(1):261-9.
View in: PubMed

Crude drugs as anticancer agents. Int J Clin Exp Med. 2011; 4(1):17-25.
View in: PubMed

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jan; 13(1):143-51.
View in: PubMed

A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1422-7.
View in: PubMed

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32.
View in: PubMed

Medical therapies for meningiomas. J Neurooncol. 2010 Sep; 99(3):365-78.
View in: PubMed

American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section. Expert Rev Anticancer Ther. 2010 Sep; 10(9):1367-9.
View in: PubMed

Effects of local tissue conductivity on spherical and realistic head models. Australas Phys Eng Sci Med. 2010 Sep; 33(3):233-42.
View in: PubMed

Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials. Neuroimaging Clin N Am. 2010 Aug; 20(3):425-48.
View in: PubMed

Recurrent high-grade glioma. Curr Treat Options Neurol. 2010 Jul; 12(4):321-33.
View in: PubMed

Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol. 2011 Feb; 101(3):487-93.
View in: PubMed

Eliciting protective immune responses against murine myeloma challenge in lymphopenia mice through adoptive transfer of tumor antigen-specific lymphocytes and immunization of tumor vaccine secreting mIL-21. Cancer Gene Ther. 2010 Oct; 17(10):675-83.
View in: PubMed

Intravascular lymphomatosis and intracerebral haemorrhage. Neurol Sci. 2010 Dec; 31(6):793-7.
View in: PubMed

Uncertainty and sensitivity analysis for anisotropic inhomogeneous head tissue conductivity in human head modelling. Australas Phys Eng Sci Med. 2010 Jun; 33(2):145-52.
View in: PubMed

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
View in: PubMed

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010 May-Jun; 60(3):166-93.
View in: PubMed

A systematic study of head tissue inhomogeneity and anisotropy on EEG forward problem computing. Australas Phys Eng Sci Med. 2010 Mar; 33(1):11-21.
View in: PubMed

Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role? J Clin Oncol. 2010 Apr 20; 28(12):1977-9.
View in: PubMed

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72.
View in: PubMed

Morphological characteristics of brain tumors causing seizures. Arch Neurol. 2010 Mar; 67(3):336-42.
View in: PubMed

Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol. 2010 Jun; 12(6):603-7.
View in: PubMed

Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2010 Sep 01; 78(1):85-90.
View in: PubMed

Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010 May; 12(5):466-72.
View in: PubMed

Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep. 2010 Jan; 12(1):68-75.
View in: PubMed

Cerebral spinal fluid abnormalities in patients with paraneoplastic syndromes of the nervous system. J Neurol Neurosurg Psychiatry. 2010 Jan; 81(1):3.
View in: PubMed

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal. 2009 Dec 15; 2(101):ra82.
View in: PubMed

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010 Jan; 12(1):95-103.
View in: PubMed

A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010 Jan; 12(1):87-94.
View in: PubMed

New therapies for recurrent glioblastomas. F1000 Med Rep. 2009 Dec 09; 1.
View in: PubMed

Treatment of recurrent high-grade gliomas. Curr Opin Neurol. 2009 Dec; 22(6):657-64.
View in: PubMed

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 2009 Dec; 11(6):853-60.
View in: PubMed

Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol. 2009 Nov; 5(11):610-20.
View in: PubMed

Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res. 2009 Oct 15; 15(20):6430-7.
View in: PubMed

Preparation of aligned porous gelatin scaffolds by unidirectional freeze-drying method. Acta Biomater. 2010 Mar; 6(3):1167-77.
View in: PubMed

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 01; 27(28):4733-40.
View in: PubMed

Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol. 2009 Oct; 6(10):596-603.
View in: PubMed

Graft-versus-host disease of the CNS after allogeneic bone marrow transplantation. J Clin Oncol. 2009 Oct 20; 27(30):e147-9.
View in: PubMed

Identification of tumor stem-like cells in a mouse myeloma cell line. Cell Mol Biol (Noisy-le-grand). 2009 Aug 05; 55 Suppl:OL1151-60.
View in: PubMed

Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Expert Opin Investig Drugs. 2009 Jul; 18(7):973-83.
View in: PubMed

Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics. 2009 Jul; 6(3):513-26.
View in: PubMed

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010 Jan; 96(2):211-7.
View in: PubMed

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009 Jul 01; 69(13):5296-300.
View in: PubMed

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20; 27(21):3518-25.
View in: PubMed

Superficial primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical analysis of 15 cases. Dis Esophagus. 2010 Feb; 23(2):153-9.
View in: PubMed

Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2035.
View in: PubMed

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). J Clin Oncol. 2009 May 20; 27(15_suppl):2004.
View in: PubMed

Phase II trial of oral gimatecan in adults with recurrent glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2009.
View in: PubMed

Interaction between sorafenib and erlotinib. J Clin Oncol. 2009 May 20; 27(15_suppl):2500.
View in: PubMed

A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J Clin Oncol. 2009 May 20; 27(15_suppl):2047.
View in: PubMed

Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J Clin Oncol. 2009 May 20; 27(15_suppl):2005.
View in: PubMed

Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13010.
View in: PubMed

Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2009 May 20; 27(15_suppl):2049.
View in: PubMed

Phase I study of vandetanib with radiation therapy and temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2031.
View in: PubMed

Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J Clin Oncol. 2009 May 20; 27(15_suppl):2006.
View in: PubMed

Circulating cytokine and angiogenic factors as predictive biomarkers of glioblastoma response to aflibercept (VEGF Trap). J Clin Oncol. 2009 May 20; 27(15_suppl):2029.
View in: PubMed

Use of neurovascular imaging in GBM patients (pts) to quantify early physiologic changes after treatment with XL184, an inhibitor of multiple receptor tyrosine kinases: Results from a phase II study. J Clin Oncol. 2009 May 20; 27(15_suppl):2048.
View in: PubMed

Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas. J Clin Oncol. 2009 May 20; 27(15_suppl):2062.
View in: PubMed

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009 Jun 20; 27(18):2905-8.
View in: PubMed

Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009 May; 9(3):231-40.
View in: PubMed

Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother. 2009 Apr; 9(4):519-34.
View in: PubMed

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 2009 Oct; 11(5):550-5.
View in: PubMed

Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol. 2009 Aug; 94(1):97-101.
View in: PubMed

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009 Mar; 144(6):895-903.
View in: PubMed

Neurological complications in adults. Cancer Treat Res. 2009; 150:113-32.
View in: PubMed

New developments in targeted molecular therapies for glioblastoma. Expert Rev Anticancer Ther. 2009 Jan; 9(1):7-10.
View in: PubMed

Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009 Jan 01; 15(1):330-7.
View in: PubMed

Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr Opin Neurol. 2008 Dec; 21(6):736-44.
View in: PubMed

Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008 Dec; 7(12):1152-60.
View in: PubMed

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol. 2009 Apr; 92(2):149-55.
View in: PubMed

Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol. 2008 Nov; 20(6):652-61.
View in: PubMed

DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. J Clin Oncol. 2008 Oct 10; 26(29):4843-4.
View in: PubMed

CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res. 2008 Sep 01; 14(17):5626-34.
View in: PubMed

Colon perforation during antiangiogenic therapy for malignant glioma. Neuro Oncol. 2009 Feb; 11(1):92-5.
View in: PubMed

Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. J Neurooncol. 2008 Sep; 89(3):339-57.
View in: PubMed

Response criteria for glioma. Nat Clin Pract Oncol. 2008 Nov; 5(11):634-44.
View in: PubMed

Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol. 2009 Apr; 11(2):109-21.
View in: PubMed

Malignant gliomas in adults. N Engl J Med. 2008 Jul 31; 359(5):492-507.
View in: PubMed

Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass. J Clin Oncol. 2008 Jul 01; 26(19):3279-81.
View in: PubMed

CNS Hodgkin lymphoma. Blood. 2008 Sep 01; 112(5):1658-61.
View in: PubMed

Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol. 2008 Aug; 10(4):631-42.
View in: PubMed

Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases. J Neurooncol. 2008 Jun; 88(2):175-83.
View in: PubMed

Influence of white matter inhomogeneous anisotropy on EEG forward computing. Australas Phys Eng Sci Med. 2008 Jun; 31(2):122-30.
View in: PubMed

A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):222-7.
View in: PubMed

A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol. 2008 May 20; 26(15_suppl):2010b.
View in: PubMed

Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. J Clin Oncol. 2008 May 20; 26(15_suppl):2051.
View in: PubMed

Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 2008 Jun; 10(3):300-8.
View in: PubMed

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008 Apr; 8(4):541-53.
View in: PubMed

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008 Mar 04; 70(10):779-87.
View in: PubMed

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008 Apr; 10(2):162-70.
View in: PubMed

Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007 Dec 15; 13(24):7401-6.
View in: PubMed

Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res. 2007 Dec 01; 13(23):7133-8.
View in: PubMed

Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther. 2007 Nov; 7(11):1537-60.
View in: PubMed

Medical management of brain tumor patients. Neurol Clin. 2007 Nov; 25(4):1035-71, ix.
View in: PubMed

Novel therapies for malignant gliomas. Neurol Clin. 2007 Nov; 25(4):1141-71, x.
View in: PubMed

Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol. 2008 Jan; 86(2):211-5.
View in: PubMed

Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol. 2008 May; 61(6):1059-67.
View in: PubMed

Chemotherapy for low-grade gliomas: emerging consensus on its benefits. Neurology. 2007 May 22; 68(21):1762-3.
View in: PubMed

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol. 2007 Jul; 9(3):354-63.
View in: PubMed

The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst. 2007 Apr 18; 99(8):639-52.
View in: PubMed

Inhibiting kinases in malignant gliomas. Expert Opin Ther Targets. 2007 Apr; 11(4):473-96.
View in: PubMed

Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note. Neurology. 2007 Mar 20; 68(12):955-6.
View in: PubMed

Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. J Neurooncol. 2007 Sep; 84(2):179-83.
View in: PubMed

Cerebrospinal fluid spread of anaplastic glioma. J Clin Oncol. 2007 Feb 10; 25(5):596-7.
View in: PubMed

A Phase II Trial Of Lapatinib And Pazopanib For Patients With Recurrent Glioblastoma Multiforme (GBM). Society For Neuro-Oncology 12th Annual Meeting. 2007.

Targeted drug therapy for meningiomas. Neurosurg Focus. 2007; 23(4):E12.
View in: PubMed

Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (NABTC 04-02). Proc ASCO. 2007.

A phase II trial of AZD2171 (cediranib) an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomas. Proc ASCO. 2007; Abstr 2001.

Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients with non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II study. Proc ASCO. 2007.

Pilot safety study of lenalidomdie and radiation therapy in patients with newly diagnosed glioblastoma. American Academy of Neurology 59th Annual Meeting. 2007.

Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMX) in patients with malignant gliomas (NABTC 04-03). Proc ASCO. 2007.

Volumetric MRI- Key to finding better treatments for plexiform neurofibromas? [commentary]. Neurology. 2007; 68:627.

Selected Topics in Cancer Neurology. 2007.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
View in: PubMed

Central nervous system toxicity from cancer therapies. Hematol Oncol Clin North Am. 2006 Dec; 20(6):1377-98.
View in: PubMed

Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006 Dec 01; 66(23):11502-13.
View in: PubMed

Coherent polyatomic dynamics studied by femtosecond time-resolved photoelectron spectroscopy: dissociation of vibrationally excited CS2 in the 6s and 4d Rydberg states. J Chem Phys. 2006 Nov 07; 125(17):174314.
View in: PubMed

Glioma therapy in adults. Neurologist. 2006 Nov; 12(6):279-92.
View in: PubMed

Multiple myeloma ployneuropath before and after initial chemotherapy with single-agent bortezomib. 131st Annual Meeting of the American Neurological Association. 2006.

Chemotherapy and targeted molecular therapies for brain metastases. Expert Rev Neurother. 2006 Oct; 6(10):1465-79.
View in: PubMed

Novel therapies for meningiomas. Expert Rev Neurother. 2006 Oct; 6(10):1447-64.
View in: PubMed

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007 Feb; 81(3):271-7.
View in: PubMed

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006 Sep 20; 24(27):4517-20.
View in: PubMed

EEG human head modelling based on heterogeneous tissue conductivity. Australas Phys Eng Sci Med. 2006 Sep; 29(3):235-40.
View in: PubMed

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006 Aug 15; 12(16):4899-907.
View in: PubMed

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006 Aug 01; 24(22):3651-6.
View in: PubMed

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology. 2006 Jul 11; 67(1):156-8.
View in: PubMed

Medical management of patients with brain tumors. J Neurooncol. 2006 Dec; 80(3):313-32.
View in: PubMed

Phase II study of POLY-ICLC in recurrent anaplastic glioma-A North American Brain Tumor Consortium study. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1550.
View in: PubMed

Phase II study of antiangiogenic (metronomic) chemotherapy for recurrent malignant gliomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1569.
View in: PubMed

Phase I trial and pharmacokinetic study of oral gimatecan in adults with malignant glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1559.
View in: PubMed

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 Jul 01; 24(19):3113-20.
View in: PubMed

Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. Expert Rev Anticancer Ther. 2006 May; 6(5):733-54.
View in: PubMed

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006 Apr; 8(2):189-93.
View in: PubMed

Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist. 2006 Feb; 11(2):152-64.
View in: PubMed

Phase I study of erlotinib and temsirolimus in patients with recurrent malignant gliomas (NABTC 04-02). Society for Neuro-Oncology 11th Annual Meeting. 2006.

Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol. 2006 Jan; 8(1):38-46.
View in: PubMed

SCH66336 (Sarasar(R)), an Oral Farnesyl Transferase Inhibitor, Synergizes with Temozolomide and Radiation Therapy for Orthotopic Malignant Gliomas. International Brain Tumor Research and Therapy Meeting. 2006.

Targeted molecular therapy of malignant gliomas. Curr Oncol Rep. 2006 Jan; 8(1):58-70.
View in: PubMed

The alkylphospholipd perifosine inhibits Akt and sensitezes murine and human glioma cells to radiation in in vitro and in vivo. Society for Neuro-Oncology 11th Annual Meeting. 2006.

Handbook fo Chemotherapy for Brain Tumors [book review]. Oncology. 2006; 20:430.

Effects of the HSP90 Inhibitor 17-AAG in Glioblastoma Multiforme. Internation Brain Tumor Research and Therapy Meeting. 2006.

Phase II Study of Imatinib Mesylate (STI571) for Patients with Recurrent Meningiomas (NABTC 01-08). Socity for Neuro-Oncology 11th Annual Meeting. 2006.

High throughput proteomic identification and quantification of MGMT in human brain tumors. Society for Neuro-Oncology 11th Annual Meeting. 2006.

Effects of the HSP90 Inhibitor 17-AAG inGlioblastoma Multiforme. Society for Neuro-Oncology 11th Annual Meeting. 2006.

Medical Management of Brain Tumors. 2006.

Neurologic complications of chemotherapy. Medlink. 2006.

A Phase I Clinical Trial and Phamacokinetic Study of Oral ST1481 in Adults with Malignant Glioma. Proc ASCO. 2006.

Targeted Molecular Therapies for Brain Tumors. 2006.

Brain metastases. Curr Opin Neurol. 2005 Dec; 18(6):654-61.
View in: PubMed

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res. 2005 Nov 01; 11(21):7841-50.
View in: PubMed

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2005 Sep 20; 23(27):6647-56.
View in: PubMed

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug; 23(4):357-61.
View in: PubMed

Suspected spinal cord compression in cancer patients: a multidisciplinary risk assessment. J Support Oncol. 2005 Jul-Aug; 3(4):305-12.
View in: PubMed

A phase II study of prolonged daily temozolomide for low-grade glioma. J Clin Oncol. 2005 Jun; 23(16_suppl):1522.
View in: PubMed

Targeted molecular therapy of malignant gliomas. Curr Neurol Neurosci Rep. 2005 May; 5(3):186-97.
View in: PubMed

A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res. 2005 Mar 01; 11(5):1685-6.
View in: PubMed

Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial [commentary]. Neurology. 2005; 64.

Presentations and Approaches to Patients with Brain Tumors. Schiff D, O'Neil BP, editors. cancer in the Nervous System. 2005.

Treatment of brain metastases in good prognosis patients. Up-To-Date. 2005.

Molecular study of malignant gliomas treated with the EGFR inhibitor, elotinib (OSI-774): Tissue analysis from a North American Brain Tumor Consortium (NABTC) study. Clin Cancer Res. 2005; 11:7841-7850.

A Phase I trial of AP23573, a novel mTOR Inhibitor in patients with recurrent malignant glioma. AARC-NCI-EORTC Internation Conference on Melecular Targets and Cancer Therapeutics. 2005.

Anticoagulant and antiplatelet therapy in patients with brain tumors. UpToDate. 2005.

Chemotherapy for brain metastases. Up-To-Date. 2005.

Cnetral Nervous system Tumors. American Society of Clincial Oncology 2005 Annual Meeting Summaries. 2005; 32-40.

Management of non-neoplastic problems in brain tumor patients. Black PM, Loeffler JS, editors. Cancer of Nervous System. 2005; 243-254.

Management of seizures in patients with primary and metastatic brain tumors. UpToDate. 2005.

Perfusion Imaging of Hemangioblastoma: Implications for using arterial spin labeling to characterize tumor dynamics. ISMR. 2005.

A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma. Proc ASCO. 2005.

Update of Radiosurgery for Brain Metastases. 2005.

Overview of brain metastases. Up-to-Date. 2005.

A Phase I Trial of R115777 in Patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs (EIAEDs): A North American Brian Tumor Consortium Study. J Clin Oncol. 2005; (23):6647-6656.

Treatment of Brain Metastases in poor prognosis patients. Up-To-Date. 2005.

A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly Hgi9h Rates of Baseline Peripheral Neuropathy. American Society for Hematology 47th Annual Meeting. 2005.

Management of vasogenic edema in patients with brain tumors. Up-To-Date. 2005.

Targeted Molecular Therapies for Malignant Gliomas. 2005.

Combination of Temozolomide and Irinotecan showed enhanced activity for recurrent malignant gliomas: A North American Brain Tumor Consoritum (NABTC) Phase II study. Proc ASCO. 2005.

Palliative Care in Neurology, Oxford Press 2004. Voltz et al. (eds) [book review]. j Palliative Care. 2005; 8:1067-8.

Palliative Care Consultations- Primary and metastatic brain tumours, Oxford Press, 2005, Booth and Bruera (eds) [book review]. J Palliative Care. 2005; (8):1068-9.

Non-cytotoxic drugs as potential treatments for gliomas. Curr Opin Neurol. 2004 Dec; 17(6):663-73.
View in: PubMed

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 2004 Nov; 22(4):427-35.
View in: PubMed

Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004 Nov 01; 22(21):4282-9.
View in: PubMed

Therapy for recurrent malignant glioma in adults. Expert Rev Anticancer Ther. 2004 Oct; 4(5):759-82.
View in: PubMed

Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1504.
View in: PubMed

Pharmacokinetics of gimatecan, and orally administered camptothecin analogue, in patients with malignant gliomas. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2039.
View in: PubMed

NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1510.
View in: PubMed

A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1502.
View in: PubMed

Comparison of 1D, 2D, 3D and volumetric parameters in measuring tumor response in high-grade gliomas in adults. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1523.
View in: PubMed

Malignant gliomas. Curr Neurol Neurosci Rep. 2004 May; 4(3):218-27.
View in: PubMed

Nervous system metastases. Bradley W, Daroff R, Fenichel G, Jankovic J, editors. Neurology in Clinical Practice. 2004; 1441-1460.

Neuro-Oncology. Samuels MA, editor. Manual of Neurologic Therapeutics. 2004; 115-178.

Brain Tumors. Baker and Joynt's Clinical Neurology on CD-ROM. 2004.

Phase II Trial of Single Agent VELCADE (bortezomib) in patients with previously untreated multiple myeloma. American Society for Hematology 46th Annual Meeting. 2004.

Epidural disease. Harris J, Lippman M, Morrow M, Kent Osborne C, editors. Diseases of the Breast. 2004; 1219-1231.

Brain Metastases in patients with breast cancer. Harris J, Lippman M, Morrow M, Kent Osborne C, editors. Diseases of the Breast. 2004; 1205-1218.

Phase II Study of Temozolomide, Thalidomide and Celecoxib in Patients with Newly-Diagnosed Glioblastomas Multiforme in the Post-Radiation Setting. Neuro-Oncology. 2004; Abstr. TA-64.

Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A North American Brain Tumor Consortium study. Proc ASCO. 2004.

Neurologic complications of lymphoma therapy. Batchelor TT, editor. Nervous System Lymphoma. 2004; 149-182.

Neurologic Complications of Cancer Therapy. 2004.

Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):44-54.
View in: PubMed

Pharmacokinetics of gimatecan and orally administerd camptothecin analogue, in patients with malignant gliomas. Proc ASCO. 2004.

Thalidomide-induced thromboembolic events in patients with high-grade gliomas. Neuro-Oncology. 2004; Abstr TA-11.

Brain Metastases-Emerging role of Radiosurgery. 2004.

A Phase II trial of OSI-774 (Tarceva) in patients with Recurrent Malignant Gliomas not on EIAEDs. Proc ASCO. 2004.

NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. Proc ASCO. 2004.

Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma: Final Report. American Academy of Neuorlogy, 56th Annual Meeting. 2004.

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003 Jun 15; 21(12):2299-304.
View in: PubMed

Neurologic complications of cancer. Preface. Neurol Clin. 2003 Feb; 21(1):xi-xiii.
View in: PubMed

Neurologic complications of cancer therapy. Neurol Clin. 2003 Feb; 21(1):279-318, x.
View in: PubMed

Neurologic complications of solid tumors. Neurol Clin. 2003 Feb; 21(1):107-40, viii.
View in: PubMed

Neurologic complications of chemotherapy. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1134-1140.

Neurologic Complications of Cancer. Neurol Clinics. 2003.

Brain Metastases. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1101-1107.

Brain Metastases-Emerging Role of Radiosurgery. 2003.

Encephalopathy and Neuropathy. Furie B, Atkins M, Cassieth P, Mayer R, editors. Clinical Practice of Hematology-Oncology: Presentations, Diagnosis and Treatment. 2003; 32-41.

Phase II Study of Antiangiogenic Chemotherapy for Recurrenct Malignant Glioma. Neuro-Oncology. 2003; 5:357. Abstr TA-41.

CNS complications of Cancer Therapy. Schiff D, Wen P, editors. Cancer Neurology in Clinical Practice. 2003; 215-231.

Phase I/II trial of gimatecan in patients with recurrent maligngant glioma. Neuro Oncology. 2003; 5:347. Abstr TA-01.

Phase I/II study of combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: A North American Brain Tumor Consurotium (NABTC) study. ASCO. 2003.

Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy. ASCO. 2003.

General principles of management of patients with brain tumors. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1018-1024.

Neurologic complications of bone marrow transplantation. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1166-1171.

Neurologic complications of chemotherapy. Medlink Neurology. 2003.

Malignant Gliomas. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1038-1048.

Brain Metastases. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1134-1140.

Clinical Presentation and Diagnosis of Brain Tumors. Samuels MA, Fesk S, editors. Office Practice of Neurology. 2003; 1013-1017.

Uncommon brain tumors, skull base tumors, and intracranial cysts. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1092-1100.

Cancer Neurology in Clinical Practice. 2003.

Neurologic Complications of Genitourinary Malignancies. Schiff D, Wen PY, editors. Cancer Neurology in Clinical Practice. 2003; 327-338.

Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002 Jun 01; 53(2):394-400.
View in: PubMed

Medical management of patients with brain tumors. Curr Opin Oncol. 2002 May; 14(3):299-307.
View in: PubMed

Management of Brain Tumors. Up-To-Date in Oncology. 2002.

Neurologic complications of cancer therapy. Up-To-Date in Oncology. 2002.

Brain Metastases. Up-To-Date in Oncology. 2002.

Detection of early atherosclerosis with radiolabeled monocyte chemoattractant protein-1 in prediabeteic Zucker rats. Pediatr Radiol. 2001 Dec; 31(12):827-35.
View in: PubMed

Transplant coronary artery disease: a novel model independent of cellular alloimmune response. Circulation. 2001 Nov 20; 104(21):2615-9.
View in: PubMed

Gliomas arising in organ transplant recipients: an unrecognized complication of transplantation? Neurology. 2001 Oct 23; 57(8):1486-8.
View in: PubMed

Comparison study of different head model structures with homogeneous/inhomogeneous conductivity. Australas Phys Eng Sci Med. 2001 Mar; 24(1):31-6.
View in: PubMed

Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 association, and regulates stability and function of the cadherin/catenin adhesion complex. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2381-6.
View in: PubMed

Clinical Imaging and Diagnosis of Brain Tumors. Laws E, Kaye A, editors. Brain Tumors. 2001; 217-248.

Metastatic Brain Cancer. DeVita VT, Hellman S, Rosenberg SA, editors. Principles and Practice of Oncology. 2001; 2655-2670.

Brain metastases. Curr Treat Options Oncol. 2000 Dec; 1(5):447-58.
View in: PubMed

Systemic metastasis in glioblastoma may represent the emergence of neoplastic subclones. J Neuropathol Exp Neurol. 2000 Dec; 59(12):1044-50.
View in: PubMed

Constructing head models by computation. IEEE Eng Med Biol Mag. 2000 Nov-Dec; 19(6):82-7.
View in: PubMed

Distant enhancers stimulate the albumin promoter through complex proximal binding sites. J Biol Chem. 2000 Sep 15; 275(37):29031-41.
View in: PubMed

Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 May 23; 54(10):1886-93.
View in: PubMed

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000 Feb; 18(4):708-15.
View in: PubMed

Brain metastases in patients with breast cancer. Harris J, Lippman M, Morrow M, Kent Osborne C, editors. Disease of the Breast. 2000.

Practice parameters: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology. 2000; 54:1886-1893.

Management of brain metastases. Oncology (Williston Park). 1999 Jul; 13(7):941-54, 957-61; discussion 961-2, 9.
View in: PubMed

Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia. 1999 Mar; 40(3):341-4.
View in: PubMed

Clinical Presentation, Evaluation and Preoperative Preparation of the Patient. Berger MS, Wilson CB, editors. Textbook of Gliomas. 1999; 328-344.

Assessing suspected spinal cord compression: a multidisciplinary outcomes analysis of 342 episodes. Support Care Cancer. 1999 Jan; 7(1):31-8.
View in: PubMed

Spinal Ependymomas. Gilman S, Goldstein GW, Waxman SG, editors. Neurobase. 1999.

Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg. 1999 Jan; 90(1):72-7.
View in: PubMed

[Influence of icariin on cell membrane of highly metastatic human lung tumor cell line]. Zhong Yao Cai. 1999 Jan; 22(1):35-6.
View in: PubMed

Role of chemotherpay in patients with gliomas. 1999.

Suspected spinal cord compression in breast cancer patients: a multidisciplinary risk assessment. Breast Cancer Res Treat. 1998 Sep; 51(2):121-31.
View in: PubMed

Dehydroepiandrosterone reduces proliferation and differentiation of 3T3-L1 preadipocytes. Biochem Biophys Res Commun. 1998 Jul 30; 248(3):497-504.
View in: PubMed

Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther. 1998 Jul 01; 9(10):1409-17.
View in: PubMed

5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med. 1998 Jul; 39(7):1148-54.
View in: PubMed

Neurologic emergencies in cancer patients. Neurol Clin. 1998 May; 16(2):449-83.
View in: PubMed

Immune parameters affecting adenoviral vector gene therapy in the brain. J Neurovirol. 1998 Apr; 4(2):194-203.
View in: PubMed

Results of linear accelerator-based radiosurgery for intracranial meningiomas. Neurosurgery. 1998 Mar; 42(3):446-53; discussion 453-4.
View in: PubMed

A novel nk-2-related transcription factor associated with human fetal liver and hepatocellular carcinoma. J Biol Chem. 1998 Jan 30; 273(5):2917-25.
View in: PubMed

Emergency Neurology. Neurologic clinics. 1998.

Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. Int J Radiat Oncol Biol Phys. 1998 Jan 01; 40(1):65-70.
View in: PubMed

Pulmonary intralobar sequestration in a patient with cystic fibrosis. Hum Pathol. 1997 Dec; 28(12):1436-9.
View in: PubMed

Guillain-Barré syndrome following allogeneic bone marrow transplantation. Neurology. 1997 Dec; 49(6):1711-4.
View in: PubMed

Dehydroepiandrosterone-sulfate (DHEAS) reduces adipocyte hyperplasia associated with feeding rats a high-fat diet. Int J Obes Relat Metab Disord. 1997 Nov; 21(11):1058-64.
View in: PubMed

Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med. 1997 Oct; 3(10):1145-9.
View in: PubMed

Cerebral hemorrhage in a patient taking fenfluramine and phentermine for obesity. Neurology. 1997 Aug; 49(2):632-3.
View in: PubMed

Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med. 1997 Apr; 3(4):437-42.
View in: PubMed

Intrathecal 5-[125I]iodo-2'-deoxyuridine in a rat model of leptomeningeal metastases. J Nucl Med. 1997 Mar; 38(3):386-90.
View in: PubMed

A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas. Clin Cancer Res. 1997 Mar; 3(3):381-7.
View in: PubMed

Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol. 1997 Feb; 15(2):723-34.
View in: PubMed

Retroviral-meicated transduction of a modified platelet factor-4 cDNA inhibits angiogenesis and tumor growth. Nature Medicine. 1997; 3:437-442.

Comparison of uptake of 99mTc-alkylisonitriles in the rat 9L gliosarcoma tumor model. Nucl Med Biol. 1997 Jan; 24(1):21-5.
View in: PubMed

Leptomeningeal Metastases. Black PMcL, Loeffler JS, editors. Cancer of the Nervous System. 1997; 288-309.

Diagnosis of Management of Brain Tumors. Black PMcL, Loeffler JS, editors. Cancer of the Nervous System. 1997; 106-127.

Neurologic Complications of Chemotherapy. Gilman S, Goldstein GW, Waxman SG, editors. Neurobase. 1997.

Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther. 1996 Jun; 3(6):513-20.
View in: PubMed

Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med. 1996 May; 2(5):567-73.
View in: PubMed

In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther. 1996 Apr 10; 7(6):713-20.
View in: PubMed

Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor. J Nucl Med. 1996 Apr; 37(4 Suppl):19S-22S.
View in: PubMed

Neurologic complications of cancer. 1996.

Management of Patients with brain tumors. 1996.

Noninvasive perfusion imaging of human brain tumors with EPISTAR. Eur Radiol. 1996; 6(4):518-22.
View in: PubMed

[Hypoxia induced increase of MDA and echinocytes from erythrocytes in rabbit's blood with special reference to inhibition of the increase by MPEG-SOD]. Sheng Li Xue Bao. 1995 Dec; 47(6):565-72.
View in: PubMed

High-grade astrocytomas. Neurol Clin. 1995 Nov; 13(4):875-900.
View in: PubMed

Uncommon brain tumors. Neurol Clin. 1995 Nov; 13(4):953-74.
View in: PubMed

Migraine with aura as the presentation of leukemia. Headache. 1995 Oct; 35(9):560-2.
View in: PubMed

Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother. 1995 Oct; 41(4):227-35.
View in: PubMed

[8%-9% and 12%-13% hypoxic gas induced free radicals generation in rat's left and right myocardium]. Sheng Li Xue Bao. 1995 Oct; 47(5):453-62.
View in: PubMed

[Acute hypoxia induce free radicals generation in rat's cortex and hippocampus]. Sheng Li Xue Bao. 1995 Oct; 47(5):510-4.
View in: PubMed

Radiosurgery for Intracranial Malignancies. Semin Radiat Oncol. 1995 Jul; 5(3):225-234.
View in: PubMed

Enhancer sharing in a plasmid model containing the alpha-fetoprotein and albumin promoters. DNA Cell Biol. 1995 Mar; 14(3):267-72.
View in: PubMed

Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995 Feb; 36(2):275-82; discussion 282-4.
View in: PubMed

Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst. 1995 Jan 04; 87(1):34-40.
View in: PubMed

Introduction to Brain Tumors in Adults. Neurologic Clinics. 1995; 13:953-974.

Stereotactic radiotherapy for meningiomas. Alexander E, Kondzioloka D, Lindquist C, Loeffler JS, editors. Radiosurgery. 1995; 1:47-54.

Malignant Gliomas. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 836-844.

Clinical Imaging and Laboratory Diagnosis of Brain Tumors. Kaye A, Shaw E, editors. Brain Tumors. 1995; 191-214.

Neurologic complications of brain tumor therapy. 1995.

Uncommon Brain Tumors. 1995.

Advances in the diagnosis and management of pituitary tumors. Curr Opin Oncol. 1995 Jan; 7(1):56-62.
View in: PubMed

Clinical Presentation and Diagnosis of Brain Tumors. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 813-817.

Reoperation following radiosurgery of gliobastoma: impact on survival and neurologic statuts. Alexander E, Kondzioloka D, Lindquist C, Loeffler JS, editors. Radiosurgery. 1995; 141-157.

Non-metastatic complications of cancer. 1995.

Initial management of gliomas including diagnosis and prognosis. 1995.

General principles of management of patients with brain tumors. Samuels MA, Fesk S, editors. Office Practice of Neurology. 1995; 817-824.

Stereotactic radiosurgery for the treatment of brain metastases: an update. Alexander E, Kondzioloka D, Lindquist C, Loeffler JS, editors. Radiosurgery. 1995; 83-91.

Uncommon brain tumors and intracranial cysts. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 887-892.

Opsoclonus-myoclonus with anti-Hu antibody [letter]. Neurology. 1995; 45:1421.

Neurologic Complications of Chemotherapy. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 914-919.

Brain Tumors in Adults. Neurologic Clinics. 1995.

Neurologic complications of bone marrow transplantation and graft versus host disease. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 944-948.

A novel hepatocytic transcription factor that binds the alpha-fetoprotein promoter-linked coupling element. Mol Cell Biol. 1994 Oct; 14(10):6616-26.
View in: PubMed

Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody. Neurology. 1994 Sep; 44(9):1754-5.
View in: PubMed

Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer. 1994 Jun 15; 73(12):3029-36.
View in: PubMed

A phase I study of etanidazole and radiotherapy in malignant glioma. Int J Radiat Oncol Biol Phys. 1994 Jun 15; 29(3):617-20.
View in: PubMed

Stereotactic radiosurgery treats intracranial lesions. Diagn Imaging (San Franc). 1994 May; 16(5):76-80, 107.
View in: PubMed

Non-metastatic complications of cancer. 1994.

Use of immunotoxin N901-blocked ricin in patients with small cell lung cancer. Int J Oncol. 1994; Supp 8:57-59.

Management issues in brain tumor patients. 1994.

A pilot study: Quality of Life in Pimary Brain Tumor Patients. Quality of Life Newsletter. 1994; 9:10.

Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int J Cancer Suppl. 1994; 8:57-9.
View in: PubMed

Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases. Proc Natl Acad Sci U S A. 1993 Sep 01; 90(17):8078-82.
View in: PubMed

Use of cerebral imaging in patients with headaches. Arch Intern Med. 1993 Jul 12; 153(13):1613-4.
View in: PubMed

Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993 Jun; 43(6):1111-4.
View in: PubMed

Deceptively normal ventricular fluid in lymphomatous meningitis. Arch Intern Med. 1993 Feb 08; 153(3):389-90.
View in: PubMed

Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med. 1993 Feb; 94(2):216-9.
View in: PubMed

Clinical Experience with Immunotherapy. Black PMcL, Schoene WC, Lampson LA, editors. Astrocytomas. 1993; 123-150.

Clinical Evaluation of Patients with Astrocytomas. Black, PMcL, Schoene WC, Lampson LA, editors. Astrocytomas. 1993; 26-36.

Neuroimaging for headaches [letter]. Arch Int Med. 1993; 1613.

Paraneoplastic syndromes. 1993.

Hemispheric Stroglial Neoplasms in Adults and Children. Black PMcL, LSchoene WC, Lampson LA, editors. Astrocytomas. 1993; 151-165.

Results of radiosurgery versus brachytherapy for malignant gliomas. DeSalles AAF, Goetsch SJ, editors, Stereotactic surgery and radiosurgery. 1993; 455-461.

Non-CNS complications of brain tumors. 1993.

Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol. 1992 Sep; 10(9):1379-85.
View in: PubMed

Major histocompatibility antigens in murine tumors. J Neurosurg. 1992 Jun; 76(6):1048-50.
View in: PubMed

Development of Lhermitte's sign after bone marrow transplantation. Cancer. 1992 May 01; 69(9):2262-6.
View in: PubMed

Reversed cerebral asymmetry in women with breast cancer. Lancet. 1992 Feb 29; 339(8792):523-4.
View in: PubMed

Disseminating tumor cells and their interactions with leukocytes visualized in the brain. Cancer Res. 1992 Feb 15; 52(4):1018-25.
View in: PubMed

Cancer Neurology. 1992.

MHC expression in murine tumors [letter]. J Neurosurg. 1992; 76:1048-9.

Radiosurgery for brain metastases: 5 year experience at the Brigham and Women's Hospital. Lunsford LD, editor. Stereotactic Radiosurgery Update. 1992; 383-392.

Non-surgical treatments of CNS malignancies. 1992.

Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study. Int J Radiat Oncol Biol Phys. 1992; 22(3):577-80.
View in: PubMed

A phpase 1 study of continuous infusion of etanidazole (SR2508) with brachytherapy. Int J Radiat Oncol Biol Phys. 1992; 22:577-580.

Alternative and future strategies in the treatment of malignant gliomas. Sem Rad Oncol. 1992; 36:57-68.

Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy. J Neuroimmunol. 1992 Jan; 36(1):57-68.
View in: PubMed

Acute disseminated encephalomyelitis progressing to hemorrhagic encephalitis. Neurology. 1991 Oct; 41(10):1697-8.
View in: PubMed

Parkinson's Disease: Anatomy, Pathology and Therapy (Streifler et al) [book review]. New Engl J Med. 1991; 324:1000.

Management of Brain Tumors. 1991.

Neurologic complications of cancer therapy. 1991.

Stereotactic radiosurgery for brain metastases. DeVita VT, Hellman S, Rosenberg SA, editors. Cancer Principles and Practice of Oncology Updates. 1991; 5(2):1-12.

Brain Tumors. Carskadon M, Rechtschaffen A, Richardson G, Roth G, Siegel J, editors. Encycolpedia of Sleep and Dreaming. 1991.

Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst. 1990 Dec 19; 82(24):1918-21.
View in: PubMed

Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys. 1990 Dec; 19(6):1455-62.
View in: PubMed

Specific uptake of the auger electron-emitting thymidine analogue 5-[123I/125I]iodo-2'-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Res. 1990 Aug 15; 50(16):5199-203.
View in: PubMed

The effects of irradiation on major histocompatibility complex expression and lymphocytic infiltration in the normal rat brain and the 9L gliosarcoma brain tumor model. J Neuroimmunol. 1990 May; 27(2-3):239-44.
View in: PubMed

Stereotactic radiosurgery of the brain using a standard linear accelerator: a study of early and late effects. Radiother Oncol. 1990 Apr; 17(4):311-21.
View in: PubMed

The treatment of recurrent brain metastases with stereotactic radiosurgery. J Clin Oncol. 1990 Apr; 8(4):576-82.
View in: PubMed

The effect of radiation on leukocytic infiltration and MHC expression in the rat brain and the 9L gliosarcoma brain tumor model. J. Neuroimmunology. 1990; 27:239-244.

Eukaryotic promoters drive gene expression in Escherichia coli. J Biol Chem. 1989 Oct 25; 264(30):17656-9.
View in: PubMed

Interferon therapy for recurrent gliomas. J Neurosurg. 1989 Apr; 70(4):660-1.
View in: PubMed

Interferon Therapy for Malignant Gliomas [letter]. J. Neurosurg. 1989; 70:660.

Nifedipine for Epilepsy? [letter]. British Medical Journal. 1988; 296:1069.

Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. Eur J Pharmacol. 1984 Apr 20; 100(2):155-62.
View in: PubMed

Current practice of Diagnostic Lumbar Puncture. British Medical Journal. 1984; 289:530.

[letter]. British Medical Journal. 1984; 287:1983.

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Shields Warren 430 D
Boston, MA 02215
Get Directions

Ratings

Top